Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.49 |
| ▸ | NPC1 | O15118 | 5/20 | 0.49 |
| ▸ | HTT | P42858 | 4/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.49 |
| ▸ | MITF | O75030 | 1/20 | 0.49 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | XBP1 | P17861 | 1/20 | 0.49 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15332330 | 0.86 | NPC1 (0.44) | RAB9ANPC1SMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL15332027 | 0.85 | NPC1 (0.48) | RAB9ANPC1HTTSMN1; SMN2MAPT | |
| SCHEMBL15330970 | 0.83 | ALDH1A1 (0.41) | HTTSMN1; SMN2ALDH1A1S1PR4NPSR1 | |
| SCHEMBL15331047 | 0.83 | NPC1 (0.42) | RAB9ANPC1HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL15330352 | 0.81 | NPBWR1 (0.45) | RAB9ANPC1ALDH1A1PAX8MEN1 | |
| SCHEMBL15332373 | 0.81 | MAPK14 (0.43) | RAB9ANPC1HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL10340588 | 0.81 | NPC1 (0.56) | RAB9ANPC1HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL15331012 | 0.80 | ERN1 (0.39) | ALDH1A1NPSR1MAPK1NPBWR1 | |
| SCHEMBL15332588 | 0.79 | PKM (0.46) | RAB9ANPC1HTTSMN1; SMN2ALDH1A1 | |
| SCHEMBL30121896 | 0.79 | PKM (0.46) | RAB9ANPC1HTTSMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101861312-B | 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines and pyridines and 3-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-2-phenyl pyridines as 5-HT7 receptor antagonists | LILLY CO ELI | 2014-09-03 | — | — | CN | disclosed |
| EP-2155717-B1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | LILLY CO ELI (US) | 2012-10-24 | — | — | EP | disclosed |
| US-8202873-B2 | 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines as 5-HT7 receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-06-19 | — | — | US | disclosed |
| CN-101861312-A | 2-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-3-phenyl pyrazines and pyridines and 3-[4-(pyrazol-4-ylalkyl)piperazin-1-yl]-2-phenyl pyridines as 5-HT7 receptor antagonists | LILLY CO ELI | 2010-10-13 | — | — | CN | disclosed |
| US-20100120785-A1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-05-13 | — | — | US | disclosed |
| EP-2155717-A1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008141020-A1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120785-A1 | 2-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-3-PHENYL PYRAZINES AND PYRIDINES AND 3-[4-(PYRAZOL-4-YLALKYL)PIPERAZIN-1-YL]-2-PHENYL PYRIDINES AS 5-HT7 RECEPTOR ANTAGONISTS | HTR7, HTR2C, HTR4 | RAB9A 3679/4885NPC1 1229/4885HTT 1245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.